New Inhibitor KH-CB19 for CLK Kinases and Its Role in Splicing
Author Information
Author(s): Oleg Fedorov, Kilian Huber, Andreas Eisenreich, Panagis Filippakopoulos, Oliver King, Alex N. Bullock, Damian Szklarczyk, Lars J. Jensen, Doriano Fabbro, Jörg Trappe, Ursula Rauch, Franz Bracher, Stefan Knapp
Primary Institution: University of Oxford
Hypothesis
The study investigates the potential of a new inhibitor, KH-CB19, to selectively inhibit CLK kinases and its effects on alternative splicing.
Conclusion
KH-CB19 is a highly selective inhibitor of CLK kinases that effectively modulates alternative splicing in human endothelial cells.
Supporting Evidence
- KH-CB19 showed low nM potency against CLK1 and CLK4.
- Cocrystal structures revealed a unique binding mode that does not mimic ATP.
- KH-CB19 effectively suppressed phosphorylation of SR proteins in human endothelial cells.
- The inhibitor altered splicing of tissue factor isoforms in response to TNF-α stimulation.
Takeaway
Scientists found a new drug that can help control how genes are turned on and off in cells, which is important for making different proteins.
Methodology
The study involved the discovery and characterization of the inhibitor KH-CB19, including cocrystal structure analysis and cellular assays to assess its effects on splicing.
Limitations
The study primarily focuses on in vitro assays, and the effects in vivo remain to be fully explored.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website